Last updated: 2026-09-06 15:08:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Cullinan Therapeutics, Inc. (CGEM) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $22.08, with a market capitalization of $1.44B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.68 to $23.19. This page covers its latest market performance, valuation, price trends and company information.
$1.44B | |
$21.88 | |
$59.85 | |
$5.68 | |
$22.16 | |
483.27K | |
-- | |
-- | |
$23.19 | |
$5.68 | |
-- | |
-- |
Cullinan Therapeutics, Inc. (CGEM) last closed at $22.16 as of 2026-09-04 23:32:00, unchanged from the previous close of $22.16.
During the latest regular trading session, CGEM traded between $5.68 and $59.85, with a volume of 483.27K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Cullinan Therapeutics, Inc. (CGEM) moved from $21.50 to $22.08, representing a gain of 2.70% ($0.58).
The stock traded between $21.32 and $22.29 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 598.20 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 93.7%
CGEM is currently trading at $22.08, placing it 93.7% of the way from its 52-week low of $5.68 to its 52-week high of $23.19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 109 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cullinan Therapeutics, Inc. (CGEM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.